<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-53302-2S4</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Selective killing of HIV infected, viral RNA producing cells to eliminate the viral reservoir</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Can we identify an effective pharmacological intervention consisting of inducers of cell death combined with latency
reversing agents to selectively eliminate HIV-infected cells towards an HIV cure?

Pharmacological strategies towards HIV cure largely target the latent HIV reservoir for reactivation, and rely on
recognition and elimination of reactivated cells by the host immune response. A more innovative approach to eliminate
HIV-infected cells emerging out of latency is to identify and manipulate danger-sensing, stress and apoptotic pathways in
order to selectively induce cell death (ICD) in infected cells. This proposal uses established research infrastructure of the
Erasmus MC HIV Eradication Group to characterise the critical innate immune pathways triggered by reactivated HIV, to
develop and test innovative combination latency reversal-ICD strategies in innovative ex vivo models for cure potential,
and to translate findings to HIV-infected patients.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">The aim of this project is to eliminate or reduce the viral reservoir by identifying the critical danger- sensing, stress and
apoptotic pathways activated upon HIV latency reversal and pharmacologically targeting them to selectively induce cell
death of HIV-infected cells. Identification of these pathways triggered upon reactivation, followed by therapeutic
intervention with candidate and unbiased-selected molecules can selectively kill latently infected cells. If this approach is
successful, it would bypass the dependence on cell-mediated and humoral immune responses to eliminate reactivated
virus because innate immune mechanisms will trigger cell death, resulting in either sterilising or functional curative HIV
therapies.</narrative>
  </description>
  <description type="4">
   <narrative xml:lang="EN">United Nations estimates a growing number of nearly 40 million people with HIV worldwide, burdening vulnerable
societies despite efforts to decrease transmission. Combination antiretroviral therapy (cART) is lifesaving but can
suppress, not cure, HIV. It must be taken lifelong, exposing patients to detrimental side effects, stigma, costs and
possibilities of developing drug resistance. Moreover, at least 40% of HIV-infected individuals are not accessing cART. The
UN, WHO and International AIDS Society set the goal to eliminate HIV by 2030 through finding safe, scalable cure
strategies. Therefore, this project proposes an innovative strategy towards an HIV cure.</narrative>
  </description>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2020-01-01" type="2"></activity-date>
  <activity-date iso-date="2023-12-31" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
   </organisation>
   <email>IATI@aidsfonds.nl</email>
   <website>https://aidsfonds.nl/</website>
   <mailing-address>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland, Condensatorweg 54, 1014 AX Amsterdam</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="NL" percentage="100"></recipient-country>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">STD control including HIV/AIDS</narrative>
  </sector>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C60" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget>
   <period-start iso-date="2020-01-01"></period-start>
   <period-end iso-date="2023-12-31"></period-end>
   <value currency="EUR" value-date="2020-01-01">275000</value>
  </budget>
  <transaction>
   <transaction-type code="11"></transaction-type>
   <transaction-date iso-date="2020-05-21"></transaction-date>
   <value currency="EUR" value-date="2020-05-21">275000</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-24485070">
    <narrative xml:lang="EN">EMC - Biochemistry</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-05-21"></transaction-date>
   <value currency="EUR" value-date="2020-05-21">107500</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-24485070">
    <narrative xml:lang="EN">EMC - Biochemistry</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-05-22"></transaction-date>
   <value currency="EUR" value-date="2020-05-22">107500</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-24485070">
    <narrative xml:lang="EN">EMC - Biochemistry</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-06-07"></transaction-date>
   <value currency="EUR" value-date="2021-06-07">70000</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-24485070">
    <narrative xml:lang="EN">EMC - Biochemistry</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2021-06-08"></transaction-date>
   <value currency="EUR" value-date="2021-06-08">70000</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-24485070">
    <narrative xml:lang="EN">EMC - Biochemistry</narrative>
   </receiver-org>
  </transaction>
  <related-activity ref="NL-KVK-41207989-P-52801" type="1"></related-activity>
 </iati-activity>
</iati-activities>
